The company emphasizes continued heavy R&D and G&A investment, with cash and marketable securities expected to fund operations for at least 12 more months.

An investor conference call and webcast were scheduled for 8:30 a.m. ET on the release date to discuss results and pipeline updates.

As of June 30, 2026, cash, cash equivalents, and marketable securities totaled $490.6 million, extending the cash runway into Q3 2028, with noted Q2 revenue and expense figures reflecting ongoing program activity.

Ongoing and upcoming pipeline progress includes WVE-003 for Huntington’s disease and WVE-N531 for Duchenne Muscular Dystrophy, with an investor day planned for fall 2026 to share updates.

In RNA editing, data from RestorAATion-2 support WVE-006 as a potential therapy for AATD addressing both lung and liver manifestations, with infrequent subcutaneous dosing and an FDA meeting planned by summer’s end 2026 to discuss accelerated approval pathways.

A clinical trial filing for WVE-008 in PNPLA3 liver disease is on track for the second half of 2026, with May 2026 preclinical data from the EASL Congress supporting editing of PNPLA3 I148M and favoring RNA editing over silencing as a therapeutic approach.

Shareholder equity remains strong with total assets of $558.3 million and shareholders’ equity at $453.5 million, while current and long-term liabilities total $104.8 million and issued ordinary shares show a modest value change.

The earnings miss is framed as part of broader market reporting that could lead investors to reassess near-term prospects.

Insider activity shows 10 disclosed trades over the past six months, including several purchases and sales from capital management affiliates and company executives.

Wave Life Sciences posted second-quarter 2026 revenue of $2.3 million and a net loss of $69.4 million, down from year-ago levels, with earnings missing estimates.

Investor Day in fall 2026 will showcase pipeline and platform updates across PRISM RNA medicines and multiple modalities.

Disclaimer notes caution readers about reliance on data and potential advertiser funding of content.